Literature DB >> 16495275

Activities of telithromycin, erythromycin, fluoroquinolones, and doxycycline against Campylobacter strains isolated from Finnish subjects.

Daniela Schönberg-Norio1, Marja-Liisa Hänninen, Marja-Leena Katila, Suvi-Sirkku Kaukoranta, Markku Koskela, Erkki Eerola, Jaakko Uksila, Sini Pajarre, Hilpi Rautelin.   

Abstract

The in vitro susceptibilities of 478 Campylobacter jejuni and Campylobacter coli strains isolated from Finnish subjects during 2002 to 2004 were determined. Susceptibility to erythromycin remained high, and telithromycin did not offer any advantage over erythromycin. Reduced susceptibilities to fluoroquinolones and doxycycline were detected almost exclusively among isolates of foreign origin.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16495275      PMCID： PMC1426464          DOI： 10.1128/AAC.50.3.1086-1088.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  In vitro activity of telithromycin against Gram-negative bacterial pathogens.

Authors:  D Felmingham; D J Farrell
Journal:  J Infect       Date:  2005-07-05       Impact factor: 6.072

2.  Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine.

Authors:  H P Endtz; G J Ruijs; B van Klingeren; W H Jansen; T van der Reyden; R P Mouton
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

3.  Antimicrobial susceptibilities of Campylobacter strains isolated from food animals in Belgium.

Authors:  M Van Looveren; G Daube; L De Zutter; J M Dumont; C Lammens; M Wijdooghe; P Vandamme; M Jouret; M Cornelis; H Goossens
Journal:  J Antimicrob Chemother       Date:  2001-08       Impact factor: 5.790

Review 4.  Campylobacters: the most common bacterial enteropathogens in the Nordic countries.

Authors:  H Rautelin; M L Hänninen
Journal:  Ann Med       Date:  2000-10       Impact factor: 4.709

5.  Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem.

Authors:  P F McDermott; S M Bodeis; F M Aarestrup; S Brown; M Traczewski; P Fedorka-Cray; M Wallace; I A Critchley; C Thornsberry; S Graff; R Flamm; J Beyer; D Shortridge; L J Piddock; V Ricci; M M Johnson; R N Jones; B Reller; S Mirrett; J Aldrobi; R Rennie; C Brosnikoff; L Turnbull; G Stein; S Schooley; R A Hanson; R D Walker
Journal:  Microb Drug Resist       Date:  2004       Impact factor: 3.431

6.  Emergence of fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli in subjects from Finland.

Authors:  H Rautelin; O V Renkonen; T U Kosunen
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

7.  Antimicrobial susceptibilities of Campylobacter strains isolated from Finnish subjects infected domestically or from those infected abroad.

Authors:  Hilpi Rautelin; Antti Vierikko; Marja-Liisa Hänninen; Martti Vaara
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Multidrug resistance in Campylobacter jejuni strains collected from Finnish patients during 1995-2000.

Authors:  Antti J Hakanen; Mirva Lehtopolku; Anja Siitonen; Pentti Huovinen; Pirkko Kotilainen
Journal:  J Antimicrob Chemother       Date:  2003-11-12       Impact factor: 5.790

9.  Fluoroquinolone resistance in Campylobacter absent from isolates, Australia.

Authors:  Leanne Unicomb; John Ferguson; Thomas V Riley; Peter Collignon
Journal:  Emerg Infect Dis       Date:  2003-11       Impact factor: 6.883

10.  Quinolone-resistant Campylobacter infections: risk factors and clinical consequences.

Authors:  Jørgen Engberg; Jakob Neimann; Eva Møller Nielsen; Frank Møller Aerestrup; Vivian Fussing
Journal:  Emerg Infect Dis       Date:  2004-06       Impact factor: 6.883
View more
  6 in total

1.  Inaccuracy of the disk diffusion method compared with the agar dilution method for susceptibility testing of Campylobacter spp.

Authors:  Mirva Lehtopolku; Pirkko Kotilainen; Pauli Puukka; Ulla-Maija Nakari; Anja Siitonen; Erkki Eerola; Pentti Huovinen; Antti J Hakanen
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Disk diffusion method for erythromycin and ciprofloxacin susceptibility testing of Campylobacter jejuni and Campylobacter coli.

Authors:  Christiane Gaudreau
Journal:  J Clin Microbiol       Date:  2013-01       Impact factor: 5.948

3.  Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.

Authors:  Mirva Lehtopolku; Ulla-Maija Nakari; Pirkko Kotilainen; Pentti Huovinen; Anja Siitonen; Antti J Hakanen
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

4.  Campylobacter jejuni isolates in Finnish patients differ according to the origin of infection.

Authors:  Benjamin Feodoroff; Patrik Ellström; Heidi Hyytiäinen; Seppo Sarna; Marja-Liisa Hänninen; Hilpi Rautelin
Journal:  Gut Pathog       Date:  2010-12-20       Impact factor: 4.181

5.  A nationwide study of Campylobacter jejuni and Campylobacter coli bacteremia in Finland over a 10-year period, 1998-2007, with special reference to clinical characteristics and antimicrobial susceptibility.

Authors:  Benjamin Feodoroff; Anneli Lauhio; Patrik Ellström; Hilpi Rautelin
Journal:  Clin Infect Dis       Date:  2011-10       Impact factor: 9.079

Review 6.  Antimicrobial resistance mechanisms among Campylobacter.

Authors:  Kinga Wieczorek; Jacek Osek
Journal:  Biomed Res Int       Date:  2013-06-24       Impact factor: 3.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.